DeepCyte Inc.

WILMINGTON, DE · Founded 2025 · CIK 0002107494 · Biotech · Private

AI platform that combines single-cell metabolomics with machine learning to predict drug toxicity and cellular damage mechanisms

deepcyte.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$1.4M
1 Form D · Jan 2026
8 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$1,445,536
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2352Illuminare Biotechnologies Inc—$6.0M
2353Ostentus Therapeutics, Inc.—$1.8M
2354Etheros Pharmaceuticals Corp.—$1.7M
2355DeepCyte Inc.—$1.4M
2356Unnatural Products Inc.—$23M
2357CELLULAR LOGISTICS, INC.—$1.0M
2358NEW EQUILIBRIUM BIOSCIENCES, INC.—$10M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 1 related persons
  • THEODORE ALEXANDROVExecutive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.